Revolutionizing KRAS-Targeted Therapies for Complex Challenges in Oncology

KRAS is a pivotal regulator in cellular signaling, often acquiring gain-of-function mutations in various cancers, including pancreatic, colorectal, and lung cancer. Historically deemed "undruggable," recent breakthroughs in therapies targeting the KRAS G12C mutation for lung cancer have paved the way for next-generation therapeutics. These advancements focus on specific KRAS mutations, pan-KRAS, KRAS activated states, and selective degradation.

Our approach leverages sophisticated in vivo, in vitro, ex vivo, and in silico models to mirror clinical KRAS mutations and resistance mechanisms, including those directly derived from patients. This comprehensive methodology enhances the precision of preclinical evaluations, supporting the development of agents targeting specific or pan-KRAS mutations.

We offer specialized models, either acquired from clinics or engineered in-house, and advanced disease models such as brain orthotopic PDX models and experimental CDX models for metastatic research. These models provide vital insights into metastatic progression and therapeutic responses.